Slide 1: Investor Day
Investor Day November 21, 2024
Slide 2: Welcome and Opening Remarks
Welcome and Opening Remarks Steve Willoughby Senior VP, Investor Relations, ESG, Risk 2
Slide 3: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 4: Financial Disclosures
Segment and business unit financial metrics presented and discussed today reflect management’s estimates of the Company’s future operating and reporting structure that will be effective at the beginning of Fiscal Year 2025 (December 30, 2024), and are subject to change Estimated future results and h
Slide 5: Agenda
Welcome Steve Willoughby Senior VP, Investor Relations, ESG, Risk Company Overview and Strategy Prahlad Singh, PhD President and CEO Life Sciences: Introduction Gene Lay, DVM Senior VP, Life Sciences Life Sciences: Life Sciences Solutions Craig Monell, PhD Senior VP, Reagents Agenda Life Sciences: S
Slide 6: Company Overview and Strategy: Let's get personal
Company Overview and Strategy: Let’s get personal Prahlad Singh, PhD President and CEO 6
Slide 7: The story you are going to hear
“This is the story you are going to hear… we’re revolutionizing science and transforming human lives with groundbreaking innovation.” 7
Slide 8: We are Revvity: our purpose
Our purpose Expanding the boundaries of human potential We are through science Revolutionizing human Embracing the impossible health at an accelerated to improve lives [vita] [rev] speed Our purpose in action Screening 40 million babies annually for life threatening diseases 8
Slide 9: Today, we will show how Revvity is…
Today, we will show how Revvity is… An innovative Life Well-positioned with A strategic partner A company with a A differentiated Sciences and high recurring revenue to customers bridging transformed portfolio financial profile Diagnostics company along with compelling the gap from pre-clinical that
Slide 10: An innovative and differentiated Life Sciences and Diagnostics company
We are an innovative and differentiated Life Sciences and Diagnostics company 2024E Revenue: ~$2.8B ~25% EMEA Segments Geography Products ~50% ~50% ~30% ~45% ~80% ~20% Life Sciences Diagnostics APAC Americas Recurring Non-recurring Revenue* Revenue *Consumables, services and software Powered by 11,0
Slide 11: Uniquely positioned in specialized, high-growth markets
Life Sciences Diagnostics Providing reagents, instruments, Providing assays, instruments, software and technology services, software and clinical lab services, Overview enabling pre-clinical R&D discovery enabling precision medicine and Uniquely and drug development specialty diagnostic testing posi
Slide 12: Portfolio ready to support global megatrends
With a portfolio ready to support global megatrends TAM Advancements in science and innovation ~$60B Cell & gene Precision Companion AI-enabled therapies medicine diagnostics solutions 12
Slide 13: We reimagined our portfolio by acquiring leading scientific offerings
We reimagined our portfolio by acquiring leading scientific offerings and expertise… Legacy Today Acquired substantial Divested Where we started new capabilities Analytical Analytical 1/3 Analytical Large Horizon business Molecule across Food Category of One Nexcelom and Applied markets Enhanced sci
Slide 14: Transformed revenue mix, financial profile and market position
…And have transformed our revenue mix, financial profile and market position Significantly changed Repositioned into faster-growing revenue composition markets with stronger quality of earnings Past LSD-MSD ~20% ~70% Future MSD >30% >85% Legacy revenue EUROIMMUN Normal Market Adjusted Adjusted Free
Slide 15: Streamlining segments and enhancing operational alignment
Our transformation continues as we streamline segments and enhance operational alignment… Adjusting Shifting Key Takeaways Life Sciences Applied Genomics No change to LRP assumptions New Life Sciences Majority of Applied Aligns with our new Revvity Solutions business Genomics moving into Operating M
Slide 16: Bridging the gap from discovery to cure
…Better enabling us to bridge the gap from discovery to cure Key player in high-value areas of the drug development lifecycle Discovery and development Diagnosis to cure Pre-clinical Diagnostics Discovery Clinical Commercial Screening development and monitoring Providing specialty Advanced Robust da
Slide 17: Uniquely differentiated in three ways
APPROACH Uniquely differentiated PRODUCTS in three ways: POSITIONING 17
Slide 18: Serving our customers as strategic partners
Serving our customers as APPROACH strategic partners… Supporting Pre-clinical Manufacturing Specialty Strategic partnerships drug drug drug clinical with Pharma / Biotech discovery evaluation components diagnostics across our portfolio to drive additional upside vs. the underlying market 18
Slide 19: High-value, non-commoditized offerings
…And providing high-value, PRODUCTS non-commoditized offerings Examples of unique products: Life Sciences Diagnostics Automated Indirect Novel Antibodies and Automated Newborn Research Platform Immunofluorescence Specialty Reagents Screening Workflow Testing Autoimmune TotalSeqTM Eonis Q System UNIQ
Slide 20: Driving faster growth and greater profitability
Driving faster growth and greater profitability POSITIONING LRP Growth Business Unit Positioning Profile • Cutting-edge scientific innovation drives Immunodiagnostics strong competitive positioning ~40% 9-11% • Strong recurring revenue mix with elevated Software incremental margins • Differentiated
Slide 21: Supported by a proven leadership team
Supported by a proven leadership team… Speakers of the day Magali Four Joel Goldberg Bryan Kipp Senior VP, Chief People Senior VP, Administration, Senior VP, Technology & Culture Officer General Counsel & & Licensing Secretary Prahlad Singh, PhD Gene Lay, DVM Craig Monell, PhD Kevin Willoe President
Slide 22: Focused on expanding human potential through science
…That is focused on expanding human potential through science Strengthening our presence within key, high-growth markets Accelerating transformational innovation Uniquely positioned to strategically partner with customers Implemented the Revvity Operating Model to drive operational efficiency and st
Slide 23: Putting it all together
Putting it all together Driving meaningful innovation that profoundly impacts science and human lives 23
Slide 24: Life Sciences
Life Sciences Gene Lay, DVM Senior VP, Life Sciences 24
Slide 25: Life Sciences at-a-glance
A specialized, high-growth business focused on helping solve customers’ scientific challenges Life Sciences at-a-glance ~15% Market overview Software HSD 5-year historical average organic $30B+ ~$1.4B growth TAM Segment Revenue (2024E) ~33% ~85% Adjusted operating MSD margin (2024E) 5-year market CA
Slide 26: Life Sciences Solutions
Life Sciences Solutions Craig Monell, PhD Senior VP, Reagents 26
Slide 27: Key messages
Key messages Leading portfolio High-growth potential in Meaningful Instruments portfolio and of reagents that assays is driven by opportunities for software solutions enable customers’ pre- consistent and additional growth complement our reagents, clinical R&D discoveries differentiated new in both
Slide 28: Reagents, instruments and technologies to power all stages of R&D
Reagents, instruments and technologies to power all stages of R&D Life Sciences Solutions (LSS) at-a-glance ~15% Software Life Sciences Solutions ~60% Market overview Reagents ~40% $25B+ Instruments* ~$1.4B ~$1.2B HSD TAM LS Revenue ~85% of LS 5-year historical (2024E) average organic growth MSD 5-y
Slide 29: Specialized reagents and instruments targeting higher-growth areas
Specialized reagents and instruments targeting higher-growth areas of life science research Reagents Instruments ~25% ~55% Sample prep and RUO antibodies automation ~25% ~$0.7B ~$0.5B ~40% Cellular analysis Revenue Research reagents Revenue (2024E) (2024E) ~25% In-vivo imaging ~5% Tech and licensing
Slide 30: Strong competitive positioning in innovative areas of Life Sciences
Strong competitive positioning in innovative areas of Life Sciences Key areas of focus Investigating the Reagents function of genes, proteins and cells to >75k accelerate research Reagents offered and drive discovery Cell analysis reagents Gene and cell modulation Microscopy reagents Leading instrum
Slide 31: Symbiotic connection between instruments and reagents
Strong symbiotic connection between instruments and reagents Sample Prep & Automation Cellular Analysis In-vivo Imaging Detection Liquid DNA & Protein Automated High-Content Imaging Plate Readers Handling Characterization Cell Counting Screening Cellometer Fontus LabChip Operetta CLS IVIS Spectrum 2
Slide 32: Differentiated portfolio of high-value, specialized offerings
A differentiated portfolio of high-value, specialized offerings Discovery and development Diagnosis to cure Screening Discovery Pre-clinical development Clinical Commercial Diagnostics Genomic analysis Immune cell screening GMP bioprocessing IP licensing and monitoring and analytical QC Protein anal
Slide 33: Partnering with customers to enable scientific advancement
Partnering with customers to enable scientific advancement Value proposition for our research customers: Extensive range of high-quality, novel reagents Academia / Government Pharma / Biotech Cutting-edge technologies and innovation informed by customer input ~30% ~70% Deep expertise and tailored cu
Slide 34: Innovation focused on driving growth
Innovation focused on driving growth Our Key Growth Drivers Strong and consistent Emerging science Market expansion new product innovation 6-8% LRP organic growth 34
Slide 35: Strong cadence of new product introductions
Innovation Strong cadence of new product introductions We are a market leader with more than 1,500 new, internally-developed Revenue contribution from antibodies, kits and reagents new LSS reagents by year introduced annually Focus on cells, genes and proteins used to increase the predictive validit
Slide 36: Acquired content development capabilities
Innovation Acquired content development capabilities to accelerate introduction of innovative new products 2019 2021 Content accelerates innovation Enhanced ability to accelerate Transformed immunoassay franchise immunoassay innovation across Life Sciences and Diagnostics Strengthened exposure to bi
Slide 37: Partnering on emerging fields of science
Emerging science Partnering with customers on emerging fields of science Key high- growth areas Cellular Analysis Multi-omics Proteins as Drug Targets Partnership examples Strong industry relationships support rapid innovation at the forefront of science 37
Slide 38: Organic expansion into new fields through collaboration
Market expansion Organic expansion into new fields through collaboration Overview Impact • Integrates oligos into IVD Insourcing Accelerated development: assays oligonucleotides Increased speed of IVD assay • Leverages Dharmacon development across the (Horizon) oligos for BioLegend company proteogen
Slide 39: Expanding our downstream capabilities
Market expansion Expanding our downstream capabilities GMP bioprocessing expansion Natural Strong customer Expected to be a extension of relationships enable larger meaningful driver existing capabilities downstream opportunity in the coming years Focus Cell culture Antibodies Cytokines areas media
Slide 40: Above-market growth in Life Sciences Solutions
Strong market positioning and innovation drive above-market growth in Life Sciences Solutions Growth drivers 500bps 100bps 100bps 6-8% Underlying Emerging Downstream LRP organic growth market growth science expansion Leading portfolio of Cutting-edge technologies Innovation and expansion Key message
Slide 41: Signals Software
Signals Software Kevin Willoe Senior VP, Signals Software 41
Slide 42: Key messages
Key messages Market leader Strong Collaboration Multiple offering both on-premise relationships tools that are opportunities and scalable, secure with the top Pharma deeply embedded in to drive future SaaS solutions companies researchers’ workflows growth 42
Slide 43: Software that promotes customer collaboration
Software that promotes our customers’ collaboration to accelerate innovation Signals Software at-a-glance Key Figures ~$0.2B 2024E Revenue Decades of scientific and technical expertise Leading provider of a scalable, secure, cutting-edge SaaS platform #1 1M+ in ELN software* Users Transition to SaaS
Slide 44: Key software metrics
Key software metrics Signals relies on different performance indicators than other Revvity businesses Annual Recurring Revenue Annualized Portfolio Value Net Retention Rate (ARR) Growth – SaaS Only (APV) Growth Total Expected Revenue Over the Next 12 Annual Value of Contracts in Portfolio Average Re
Slide 45: Signals' portfolio of advanced solutions
Signals’ portfolio of advanced solutions SaaS Hybrid / On-prem Intuitive knowledge capture and collaboration with self-service integration The standard drawing and collaboration tool for small molecules and bio macromolecules End-to-end workflow support across multiple scientific disciplines in R&D
Slide 46: Software solutions that span customers' workflows
Software solutions that span our customers’ workflows Discovery and development Diagnosis to cure Screening Discovery Pre-clinical development Clinical Commercial Diagnostics ChemDraw Signals Notebook Signals Clinical Spotfire for and monitoring Pharma and Signals Notebook Signals Research Suite Spo
Slide 47: Operating within a fast-growing market
Focused on supporting Research Informatics and Market Clinical Analytics workflows overview Operating ~$4B Strong presence in Pharma within a fast- Research TAM growing market Targeted offerings and white HSD space opportunity within Market growth Clinical Analytics Growing opportunity in Material S
Slide 48: Three key growth pillars in Signals
Our growth in Signals is based on three key pillars Our Key Growth Drivers Expansion with New offerings New customer wins existing customers Significant Biologics and large Recently launched Signals Improving reach with Pharma molecule expansion in 2025 Synergy and Signals Clinical Tier 2 and Tier 3
Slide 49: Innovation in our business
Existing customers Innovation in our business New offerings Future product developments focused on helping customers tackle the complexities associated with pursing new therapeutic modalities Design Logistics Biologics / Large Molecule Signals LabGistics An AI-first logistics and workflow platform C
Slide 50: Strong benefits through collaboration
New offerings Strong benefits through collaboration Leveraging internal scientific expertise Streamlined innovation and rapid iterations driven by our strong, continuous feedback loop Collaboration Internal sandbox environment with Life Customer-centric offerings based on intimate Powerful feedback
Slide 51: The SaaS transition
Existing customers The SaaS transition Signals Case Study Customer had 8+ scientific disciplines operating across multiple on-premise notebooks, each with distinct requirements and levels of complexity “Within one year of Gradually transitioned to a single Signals transitioning from our Notebook bas
Slide 52: Signals poised to grow through customer-centric innovation
Signals poised to grow through customer-centric innovations and solutions Growth drivers 500bps 250bps 250bps 9-11% Expansion with New New LRP organic growth existing customers offerings customer wins Innovating Trusted partner to leading Solution expansion Profitable business that Key messages thro
Slide 53: Specialized and high-growth Life Sciences
Specialized and high-growth Life Sciences Accelerating discoveries and driving transformative solutions Growth outlook Life Sciences Solutions Signals 6-8% 9-11% 7-9% long-term outlook long-term outlook LRP organic growth ~85% ~15% Leading portfolio Above-market growth Meaningful Instrument and of r
Slide 54: Diagnostics
Diagnostics Yves Dubaquie, PhD Senior VP, Diagnostics 54
Slide 55: Key messages
Key messages Leading the Capitalizing on Expanding Leveraging market with our internal expertise global capabilities strengths in specialty diagnostics to drive menu expansion in specialized, high- Reproductive Health and portfolio and speed-to-market growth diagnostic Immunodiagnostics categories a
Slide 56: Leadership in specialized markets
Leadership in specialized markets Diagnostics at-a-glance ~60% Market overview Immunodiagnostics MSD 5-year historical ~$1.4B $30B+ average organic growth TAM Segment Revenue (2024E) ~27% Adjusted operating MSD ~40% margin (2024E) 5-year market CAGR Reproductive Health Providing complete screening s
Slide 57: Comprehensive solutions for high-precision clinical testing
Comprehensive solutions for high-precision clinical testing Key areas of focus Autoimmunity Wide range of assays and innovative automation and allergy platforms for fast and accurate diagnostics Autoimmune assays Automated analyzers Emerging Extensive suite of assays to assess acute and ongoing infe
Slide 58: Innovations accelerate drug development and clinical decisions
Our innovations accelerate drug development and drive important clinical decisions Discovery and development Diagnosis to cure Discovery Pre-clinical Screening Diagnostics and monitoring development Newborn screening Autoimmunity Prenatal screening Allergy Clinical Genetics and genomics screening Em
Slide 59: Partnering with clinical customers on tailored solutions
We partner with our clinical customers to offer tailored solutions Value proposition Private labs Hospitals and Public health Deep expertise and strong including major universities / screening and global presence reference labs research centers testing labs End-to-end diagnostic solutions for our cu
Slide 60: Immunodiagnostics
Immunodiagnostics AN ay. | | 7 ’ i . . a renvity
Slide 61: Specialized, high-growth Immunodiagnostics
Specialized, high-growth Immunodiagnostics Strong positions in: Autoimmune Global leader with broad testing menu ~50% Autoimmune Emerging Infectious Disease ~$0.8B ~35% HSD Recent new product introductions Emerging 5-year historical continue to improve positioning in Revenue infectious disease avera
Slide 62: Attractive market potential and runway for above-market growth
Attractive market potential and huge runway for above-market growth Our Key Growth Drivers Elevated underlying market Meaningful innovation-led Significant geographic growth compared to menu expansion in existing expansion and penetration routine diagnostics and adjacent categories opportunities 9-1
Slide 63: Elevated underlying market growth compared to routine diagnostics
Market growth Elevated underlying market growth compared to routine diagnostics ANAs1 are the most common autoimmunity biomarker ANA Prevalence in the U.S. Autoimmune market highlights Est. # of Americans with ANA (in millions) 50 45 Over 80 distinct autoimmune diseases; 40 ~1 in 10 people affected
Slide 64: Continuous innovation in existing categories
Innovation Continuous innovation in existing categories Spotlight into recent product innovations Automating Latent TB Testing Versatile and Scalable ELISA ELISpot Automation EUROMicroBlot Automates the T-SPOT.TB Miniaturized immunoblots in test with the Auto-Pure 2400 microtiter plate format, scala
Slide 65: Future innovation in adjacent categories
Innovation Future innovation in adjacent categories Neurodegenerative Diseases (NDD) Active Tuberculosis Affects millions worldwide, Phase where mycobacteria are multiplying, with Alzheimer's being the most common leading to symptoms and transmission • Cases rising due to aging populations • 1.25 mi
Slide 66: Significant geographic expansion opportunity, driven by the U.S.
Geographic expansion Significant geographic expansion opportunity, driven by the U.S. Our Immunodiagnostics Highlights Geographic Revenue Mix Significant opportunity to grow in the U.S., the largest Autoimmune market in the world 60% ROW 85% Investing to drive FDA approvals 95% ROW for key programs
Slide 67: Strong Immunodiagnostics growth through innovation and expansion
Strong topline Immunodiagnostics growth through innovation and expansion Growth drivers 600bps 200bps 200bps Elevated underlying New product Geographic 9-11% market growth introductions expansion LRP organic growth Designing solutions that Driving above-market growth Pioneering advances in shorten t
Slide 68: Reproductive Health
ae Reproductive Health ~
Slide 69: Improving all stages of reproductive health
Improving all stages of reproductive health Outperforming global birth trends* through menu and geographic expansion #1 in Newborn Screening ~70% Newborn screening 40+ years of newborn screening leadership ~10% 85+ newborn lives saved daily ~$0.5B Maternal and LSD prenatal health 5-year historical L
Slide 70: Early detection helps save lives
Early detection helps save lives Screening millions of newborns with advanced technologies Comprehensive Screening Solutions Presence in Providing complete workflow Screening for 70+ conditions >100 countries and testing services including metabolic, endocrine and genetic disorders supporting local
Slide 71: Reliably growing despite global birth rate trends
Reliably growing despite global birth rate trends Our Key Growth Drivers Geographically expanding Menu adoption by New menu expansion existing assays to new adding more assays to through innovation countries existing programs 2-4% LRP organic growth 71
Slide 72: Consistent geographic expansion
Geographic expansion Consistent geographic expansion Number of countries with Newborn Screening, by decade Spotlight on key regions 100 Growing adoption of national testing programs 92 for expanded disease panels (e.g., Indonesia, 73 Oman, Dominican Republic, Algeria) 51 38 2024 WHO proclamation cre
Slide 73: Menu adoption of existing disorders to drive growth
Menu adoption Menu adoption of existing disorders to drive growth Montana: 33 disorders Ohio: 46 disorders High Meaningful dispersion in number of assays tested per baby around the world presents future opportunities California: Low 59 disorders Grassroots patient advocacy, developing economies and
Slide 74: Expanding RUSP menu and adoption through innovation
Menu expansion Expanding Recommended Uniform Screening Panel (RUSP) menu and adoption through innovation RUSP Overview: Standardized list of disorders guiding U.S. state-led universal NBS programs Opportunities Expand menu for treatable rare diseases and Total # of conditions evolve with cutting-edg
Slide 75: Menu expansion driven by innovation in early screening
Menu expansion Menu expansion driven by innovation in early screening and future technologies Metachromatic Leukodystrophy Next Generation Sequencing (MLD) for Newborn Screening New therapeutics for rare disease drive Rapid advances promise new treatments expansion of NBS panels requiring early diag
Slide 76: Consistent growth across Reproductive Health
Consistent growth across Reproductive Health Growth drivers -200bps 100bps 250bps 100bps 50bps Birth rate Geographic expansion Adoption of existing assays New product menu expansion Stability in prenatal and 2-4% LRP organic growth cord blood Newborn 3-5% Growth 1-2% Growth Complete Reproductive Lea
Slide 77: Leveraging unique capabilities for customers
Leveraging unique capabilities in innovative ways for customers Improving patient outcomes through internal expertise and infrastructure Capitalizing on internal capabilities Impact Enhanced product innovation: • Supplies BioLegend Remaining at the forefront of pre-clinical antibodies to development
Slide 78: Strong growth in specialized diagnostic markets
Strong growth in specialized diagnostic markets Innovation and execution provide above market growth opportunities Growth outlook Immunodiagnostics Reproductive Health 9-11% 2-4% 6-8% long-term outlook long-term outlook LRP organic growth ~60% ~40% Market-leading Leveraging leadership Capitalizing o
Slide 79: Connecting Through Innovation
Connecting Through Innovation Madhuri Hegde, PhD, FACMG Senior VP, Chief Scientific Officer 79
Slide 80: Medicine is rapidly changing
Medicine is rapidly changing A new era from prediction to action Transforming the fundamentals Participatory Precision Medicine Precision Medicine Personalized Screening Preventative Screening Symptomatic Medicine Predictive Symptomatic Precision medicine expected to grow Medicine at a CAGR of 15%+
Slide 81: Customers seek partners to accelerate concept to clinical impact
Customers seek partners who can accelerate their journey from concept to clinical impact Develop Screening Monitor patients specialized across patient for those same assays populations conditions and drugs Diagnosis of diseases Partner on creating Partner on a companion diagnostics (CDx) new drug or
Slide 82: Collaborating requires adaptable and multifaceted approaches
Pre-clinical development Clinical Collaborating requires adaptable Customer and multifaceted Needs approaches Commercial Discovery tailored to unique needs and goals Diagnostics and Screening monitoring 82
Slide 83: Strategically expanded capabilities to meet customer needs
We have strategically expanded our capabilities to meet the needs of our customers 83
Slide 84: We acquired capabilities to drive scientific insights and innovation
We acquired capabilities to drive scientific insights and innovation… Added tools important for the future of Added to our specialty diagnostics portfolio precision medicine including CRISPR and RNAi reagents, cell models, cell engineering and base editing offerings Low-hanging commercial and workfl
Slide 85: Bridging the gap from research to reality
…Bridging the gap from research to reality and enabling precision medicine Life Sciences Diagnostics Leveraging our unique Leading the embrace of next capabilities to help our generation diagnostic modalities customers deliver new to help our customers screen and therapeutics and treatments diagnose
Slide 86: Connecting unique capabilities to drive precision medicine
Connecting our unique capabilities to drive precision medicine Specialized Our Cutting-edge Leadership in Global clinical content Reproductive laboratory clinical & Differentiated omics development Health network expertise Right to Win 86
Slide 87: Path to omics-based precision medicine
Path to omics-based precision medicine Start of the patient’s diagnostic journey: How Revvity is involved with Duchenne Muscular Dystrophy (DMD) Early Detection: Sequencing the Generating gene entire DMD editing reagents newborn screening genome with our proprietary, Identifying FDA-approved sequenc
Slide 88: Prediction and prevention for more prevalent diseases
Prediction and prevention for more prevalent diseases Diagnostics Case Study Emerging Trend: Testing Newborns for T1D Type 1 Diabetes (T1D) Collaborating internally to meet this need Our internal capabilities: Autoantibody assay for neonatal detection Genetic risk screen and Our Reproductive progres
Slide 89: Transformational gene editing technology
Transformational gene editing technology Life Sciences Case Study Pin-PointTM base editing is perfectly situated for a wide variety of future rare disease therapies nuclease sgRNA Differentiated platform Novel IP with therapeutic advantages Highly effective single nucleotide editing (SNV) >50% of di
Slide 90: Bridging the gap from discovery to cure
We are uniquely positioned to capitalize on opportunities for growth as science and medicine rapidly evolve Bridging the gap from There is tremendous potential to capitalize on our ability discovery to innovate and create novel solutions with our customers to cure We are just getting started on this
Slide 91: Financial Strategy and Outlook
Financial Strategy and Outlook Max Krakowiak Senior VP, CFO 91
Slide 92: Key messages: financial strength and growth potential
Key messages Financial strength and growth potential Reiterating long- Well-positioned Revvity Operating range targets Meaningful capital portfolio to continue to Model to drive Organic growth of 6-8% allocation potential deliver resilient and operational efficiencies focused on increasing Adj. oper
Slide 93: Transformed portfolio and financial performance
Portfolio positioning Transformed portfolio & financial performance Adj. Revenue ($B) Adj. Operating Margin (%) 755bps Increase Highlights 28.0-28.5 2.88 2.75-2.77 20.7 Resilient revenue profile with 2019 2024E 2019 2024E ~80% recurring revenue Higher quality of earnings Adj. EPS ($) Free Cash Flow
Slide 94: Implementing the Revvity Operating Model
Operating model Implementing the Revvity Operating Model… Accountability Agility Digitalization Talent Driving innovation, customer satisfaction and strong financial performance 94
Slide 95: To capture operational synergies
Operating model …To capture operational synergies Innovation Operations Commercial Materials insourcing Cross portfolio solutions E-commerce Manufacturing automation Joint development efforts Cross-selling Logistics optimization Centers of Excellence Vendor consolidation Strategic accounts for key c
Slide 96: Future reporting structure starting in 2025
Operating model Future reporting structure starting in 2025 Figures for 2024E Current reporting Future reporting (12/30/2024) $ Organic Adj. Organic Adj. revenue operating revenue operating Revenue growth margin Revenue growth margin Reallocating the Life majority of Applied ~$1.3B -LSD 36% ~$1.4B -
Slide 97: New reporting structure timeline
Operating model New reporting structure timeline 2024 2025 Nov Jan / Feb Apr / May New reporting Report 4Q24 results Report 1Q25 results structure announced and file 2024 10-K using realigned segments using existing segment Press release with 2023 and financials 2024 recast financials for new report
Slide 98: Growth algorithm driving sustained, superior growth
Long-range plan Growth algorithm driving sustained, superior growth 5-year avg. LRP organic organic growth growth ~20% ~32% Immunodiagnostics HSD 9-11% 6-8% LRP organic 9-11% ~$2.8B Signals Software LDD growth 200bps above (2024E) revenue market in normal Life Sciences Solutions HSD 6-8% market cond
Slide 99: Multiple levers to drive gross margin expansion
Long-range plan Multiple levers to drive gross margin expansion Mix / volume Natural leverage from higher growth Operational 25bps efficiency initiatives in higher margin product categories M&A synergies across sourcing, overhead and logistics per year Pricing Gross margin Improved processes expansi
Slide 100: Significant opportunity for operational leverage
Long-range plan Significant opportunity for operational leverage Highly innovative products require less overhead growth 50bps Investments in digitalization and automation Ability to scale the business with lower incremental SG&A per year Revvity Operating Model initiatives to drive additional savin
Slide 101: Achieving top-tier margins with industry-leading potential
Long-range plan Adj. Operating Margin (%) 50bps per year Mid-30% Achieving top- 25bps per year tier margins with 28.3% industry-leading potential Incremental adj. op. margins in the upper 30s% to low 40s% 2024E Gross margin expansion SG&A operating leverage and Future cost efficiencies 101
Slide 102: Improving cash performance
Long-range plan Improving cash performance Free Cash Flow Conversion (FCF as a % of adjusted net income) Key drivers Lower capital intensity >85% >90% ~70% FCF Conversion Digital capabilities with increased CapEx Revvity Operating Model 2017-2023 2024E LRP 102
Slide 103: Balanced capital allocation strategy
Capital allocation Balanced capital allocation strategy focused on maximizing shareholder value M&A Buybacks Dividends Targeted M&A to complement capabilities Future Opportunistic share repurchases Historical (2017-2023) Intentions* (2024-2028) Maintain existing dividend ~$4B of capital capacity thr
Slide 104: Disciplined capital deployment to drive profitable growth
Capital allocation Disciplined capital deployment to drive profitable growth Capitalizing on organic and inorganic opportunities • Prioritize our fastest growing core markets Key priority areas and near adjacencies (e.g., Reagents, Software, Immunodiagnostics) Precision medicine Strategic • Accelera
Slide 105: Strong and differentiated financial outlook
Strong and differentiated financial outlook Long-term outlook 6-8% 3% Double Digits Adj. EPS growth Organic revenue growth 75bps operating (200bps above market) margin expansion Life Sciences: 7-9% Diagnostics: 6-8% Future capital deployment is incremental to the LRP outlook above 105
Slide 106: 2025 considerations
2025 considerations Market Margin Net Interest Tax Rate Environment Expansion Expense Path to To be dependent normalization on level of organic to continue into growth; significant ~$70M ~20% 2025 opportunity remains Formal 2025 guidance to be provided on Q4 earnings call 106
Slide 107: Today's Journey
Today’s Journey: New insights and a personal connection to our company 107
Slide 108: Investment thesis
Investment thesis A Category of One An innovative Life Well-positioned with A strategic partner A company with a A differentiated Sciences and high recurring revenue to customers bridging transformed portfolio financial profile Diagnostics company along with compelling the gap from pre-clinical that
Slide 109: Expanding the boundaries of human potential through science
Expanding the boundaries of human potential through science 109